Aspire Private Capital’s GSK GSK Stock Holding History

Aspire Private Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-7	Closed	-$286	–	354
2024 Q3	$286	Hold	7	–	–	﹤0.01%	634
2024 Q2	$270	Hold	7	–	–	﹤0.01%	649
2024 Q1	$300	Hold	7	–	–	﹤0.01%	674
2023 Q4	$259	Hold	7	–	–	﹤0.01%	666
2023 Q3	$253	Hold	7	–	–	﹤0.01%	664
2023 Q2	$249	Hold	7	–	–	﹤0.01%	639
2023 Q1	$249	Hold	7	–	–	﹤0.01%	618
2022 Q4	$246	Hold	7	–	–	﹤0.01%	620
2022 Q3	$0	Buy	+7	New	+$265	﹤0.01%	631
2021 Q1	–	Sell	-3	Closed	–	–	563
2020 Q4	$0	Sell	3 -6,715	-100%	-$308K	﹤0.01%	484
2020 Q3	$316K	Sell	6,718 -1,521	-18%	-$76.2K	0.13%	87
2020 Q2	$426K	Sell	8,239 -1,369	-14%	-$70.2K	0.2%	70
2020 Q1	$455K	Sell	9,608 -938	-9%	-$50K	0.25%	64
2019 Q4	$619K	Sell	10,546 -347	-3%	-$19.3K	0.27%	68
2019 Q3	$581K	Sell	10,893 -412	-4%	-$21.2K	0.28%	66
2019 Q2	$566K	Sell	11,305 -1,865	-14%	-$93.6K	0.27%	77
2019 Q1	$688K	Sell	13,170 -1,632	-11%	-$81.6K	0.35%	63
2018 Q4	$707K	Buy	+14,802	New	+$729K	0.41%	55

Other funds holding GSK

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.2B AUM 37.55% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Aspire Private Capital's GSK Position: Q4 2024 in Review

Aspire Private Capital sold out of GSK (GSK) in Q4 2024, closing a stake of 7 shares — an estimated $286 sold.

Aspire Private Capital first reported a position in GSK in Q4 2018 and held it in 18 quarters. The position peaked at $707K in Q4 2018. 848 funds tracked by Wall St. Rank hold GSK as of Q4 2024.

Aspire Private Capital reported no remaining GSK position as of Q4 2024 after selling out during the quarter.
Aspire Private Capital sold 7 GSK shares in Q4 2024, an estimated $286.
Aspire Private Capital first reported a position in GSK in Q4 2018 and held it in 18 quarters.
Aspire Private Capital's GSK position peaked at $707K in Q4 2018.
848 funds tracked by Wall St. Rank held GSK as of Q4 2024.

Based on Aspire Private Capital's 13F filing for Q4 2024, filed 17 Jan 2025.